The Influence of the Number of Presented Symptoms in Product-Claim Direct-to-Consumer Advertising on Behavioral Intentions by Wingate, Nikki & Xie, Ying
Purpose
The Influence of the Number of Presented 
Symptoms in Product-Claim Direct-to-Consumer 
Advertising on Behavioral Intentions
Nikki Wingate, Ph.D.
Ernest C. Trefz School of Business
University of Bridgeport
In order to improve the
effectiveness of product-claim
Direct-to-Consumer Advertising
(DTCA), the current research
examines the effect of a
presentational element – the
number of treatable symptoms for
the advertised medical condition
featured in the ad – on consumers’
intentions to seek treatment.
Ninety-five participants recruited at
a mall in the northeastern US
provided data on behavioral and
attitudinal intentions regarding a
product-claim print DTCA for an
antidepressant.
Featuring a high (vs. low) number of
symptoms improved the
effectiveness of the product-claim
DTCA. Seeing more symptoms led
to heightened perceptions of
informativeness, lower persuasive
intent, and higher intentions to
discuss the advertised ailment and
the advertised drug with the doctor.
Perceptions of disease prevalence
mediated this influence. The
perceived impact of each symptom
featured in the DTCA was controlled
across experimental conditions.
This research contributes to the
healthcare marketing literature by
demonstrating how managing a
presentational element in DTCA
influences consumers’ meta-
cognitive processing of the health
information and consequently their
intentions to engage in health-
related behaviors.
Within the regulatory boundaries,
pharmaceutical marketers may wish
to increase the number of treatable
symptoms to feature in their
product-claim DTCA in order to
improve the effectiveness.
Originality/value: This research
builds on the extant literature of
examining consumer perceptions of
DTCA, and suggests a practical and
metacognitive means to improve
consumer perceptions to ultimately
enhance DTCA effectiveness.
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FDA regulations state that product 
claim ads must include[1]:
Decisions under control of advertisers      
in execution
 At least one FDA-approved use for the 
drug
 Number of treatable symptoms
 Selection of treatable symptoms 
 The most significant risk(s) of the drug  Selection and interpretation of the ‘most 
significant’ risks
 Number of risk(s) to be presented
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Disease
Discuss Drug
Low 3.93 6.58 5.08 1.70 .95
High 5.18 7.60 4.00 2.95 1.58
F 6.66 8.29 4.64 12.79 8.17
p .0114 .0049 .0339 .0006 .0053
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